Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

MBCProject_1493_T1_RNA

— · A

a39e4d6c-e851-5dd8-865d-195c26b3425c

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.460
  • UV_RESPONSE_DN+0.450
  • ANGIOGENESIS+0.310
  • HEDGEHOG_SIGNALING+0.290
  • COAGULATION+0.280
  • MYOGENESIS+0.250
  • KRAS_SIGNALING_UP+0.230
  • APICAL_JUNCTION+0.190
  • COMPLEMENT+0.180
  • ADIPOGENESIS+0.110

Top 10 suppressed

  • MYC_TARGETS_V2-0.560
  • E2F_TARGETS-0.550
  • G2M_CHECKPOINT-0.500
  • MYC_TARGETS_V1-0.450
  • ESTROGEN_RESPONSE_LATE-0.420
  • MTORC1_SIGNALING-0.410
  • ESTROGEN_RESPONSE_EARLY-0.380
  • DNA_REPAIR-0.360
  • OXIDATIVE_PHOSPHORYLATION-0.350
  • GLYCOLYSIS-0.240

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR26320068
bladder-landscape@3
——0.891
2SRR8518451
breast-umap@18
—A0.881
3SRR25617871
breast-umap@18
—C0.876
4SRR8613742
breast-umap@18
—A0.873
5TCGA-B6-A0IH-01A-11R-A115-07
breast-umap@18
—A0.873
6SRR12475118
colon-landscapes@1
——0.871
7TCGA-D8-A1JU-01A-11R-A13Q-07
breast-umap@18
—A0.861
8MBCProject_0573_T2_RNA
breast-umap@18
—A0.857
9TCGA-BH-A0EA-01A-11R-A115-07
breast-umap@18
—A0.851
106b32f047-89ca-40e7-950f-a03493ea90c7
colon-landscapes@1
——0.848

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 21 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.460Inavolisib— uncovered
UV_RESPONSE_DN0.450Inavolisib— uncovered
ANGIOGENESIS0.310Remibrutinib— uncovered
HEDGEHOG_SIGNALING0.290Inavolisib— uncovered
COAGULATION0.280Binimetinib— uncovered
MYOGENESIS0.250Inavolisib— uncovered
KRAS_SIGNALING_UP0.230Inavolisib— uncovered
APICAL_JUNCTION0.190Inavolisib— uncovered
COMPLEMENT0.180Inavolisib— uncovered
ADIPOGENESIS0.110Inavolisib— uncovered
BILE_ACID_METABOLISM0.100Inavolisib— uncovered
PROTEIN_SECRETION0.100Remibrutinib— uncovered
FATTY_ACID_METABOLISM0.090Inavolisib— uncovered
TGF_BETA_SIGNALING0.090Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.090Inavolisib— uncovered
HEME_METABOLISM0.060Temsirolimus— uncovered
INFLAMMATORY_RESPONSE0.060Idelalisib— uncovered
XENOBIOTIC_METABOLISM0.060Inavolisib— uncovered
HYPOXIA0.050Idelalisib— uncovered
PANCREAS_BETA_CELLS0.040Cobimetinib— uncovered